Novus Acquisition & Development Corp. (OTC Pink: NDEV) (“Novus”), a provider of services targeting the healthcare component of the medical marijuana industry, today announced that it will roll out its health insurance and insurance related business “MedPlan” in approved Medical Marijuana (“MMJ”) states through its subsidiary Novus Medical Group, Inc.
Novus and its subsidiary, Novus Medical Group, Inc., has been cleared to offer its MedPlan in the states of Vermont and Arizona, while filing with regulatory bodies in the states of Washington, California, Colorado, Nevada and Oregon, where there are over 800,000 enrolled MMJ patients.
With this approval, Novus Medical Group, Inc. will be the first company in the MMJ space to provide access to healthcare and offer healthcare cost savings to the network of patients who wish to have alternative treatments such as MMJ and/or Hemp CBD. Patients can pre-enroll at the website of Novus Medical Group, Inc. with incentives to receive one month free, once the benefit plan is activated in their respective state, which is anticipated for October 15, 2014. Pre-enrollment can be done here; http://novusmedicalgroup.com/preenrollment.htm
“We decided to initially launch our Novus MedPlan in Arizona, where over 30,000 registered patients exist, along with the announcement last week that Veterans (50,000 in Arizona) now qualify for MMJ which gives Novus MedPlan over 80,000 patients who are enrolled or eligible in the state’s MMJ program” said Novus Acquisition & Development Corp CEO Frank Labrozzi. “Novus’s subsidiary Novus Medical Group, Inc. President, Andrea Lopez has created a medical plan benefits package putting Novus on a clear path to providing health care insurance and insurance related programs. Our goal is simply to deliver a health insurance format to patients interested in using MMJ and/or Hemp CBD in legal states.”
Novus Acquisition & Development Corp. (“Novus”) provides health insurance and related insurance solutions to the medical marijuana industry in states where legal programs exist. The Company also plans to offer physicians’ education programs, pharmaceutical R&D, compliance, and business development services within the industry.
NDEV will work as outside developers and will not cultivate, handle, transport grow, extract, dispense put up for sale, put on the market, vend, deliver, supply, circulate, trade, cannabis or any substances that violates the United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws.
For Investor Relations contact:
Main Tel: (855) 422-4463
Novus Acquisition & Development Corp
Gary F. Labrozzi
Website; www.ndev.biz or www.novusmedicalgroup.com